(VIANEWS) – Amphastar Pharmaceuticals (AMPH), Laureate Education (LAUR), Summit Financial Group (SMMF) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Amphastar Pharmaceuticals (AMPH)
45.4% sales growth and 18.12% return on equity
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Earnings Per Share
As for profitability, Amphastar Pharmaceuticals has a trailing twelve months EPS of $1.74.
PE Ratio
Amphastar Pharmaceuticals has a trailing twelve months price to earnings ratio of 36.09. Meaning, the purchaser of the share is investing $36.09 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.12%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 43.6% and 81.6%, respectively.
Moving Average
Amphastar Pharmaceuticals’s value is way higher than its 50-day moving average of $53.40 and way higher than its 200-day moving average of $38.11.
Previous days news about Amphastar Pharmaceuticals(AMPH)
- Zacks industry outlook highlights amphastar pharmaceuticals, dr. reddy's laboratories and teva pharmaceutical. According to Zacks on Monday, 14 August, "Chicago, IL - August 14, 2023 - Today, Zacks Equity Research discusses Amphastar Pharmaceuticals (AMPH Quick QuoteAMPH – Free Report) , Dr. Reddy’s Laboratories (RDY Quick QuoteRDY – Free Report) and Teva Pharmaceutical (TEVA Quick QuoteTEVA – Free Report) ."
2. Laureate Education (LAUR)
19.7% sales growth and 10.09% return on equity
Laureate Education, Inc., together with its subsidiaries, provides higher education programs and services to students through a network of universities and higher education institutions. It offers a range of undergraduate and graduate degree programs primarily in the areas of business and management, medicine and health sciences, and engineering and information technology through campus-based, online, and hybrid programs. The company provides its services in Brazil, Mexico, Chile, Peru, and the United States. The company was formerly known as Sylvan Learning Systems, Inc. and changed its name to Laureate Education, Inc. in May 2004. The company was founded in 1989 and is headquartered in Baltimore, Maryland.
Earnings Per Share
As for profitability, Laureate Education has a trailing twelve months EPS of $0.44.
PE Ratio
Laureate Education has a trailing twelve months price to earnings ratio of 32.55. Meaning, the purchaser of the share is investing $32.55 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.09%.
Moving Average
Laureate Education’s value is way higher than its 50-day moving average of $12.45 and way above its 200-day moving average of $11.52.
3. Summit Financial Group (SMMF)
19.6% sales growth and 13.87% return on equity
Summit Financial Group, Inc. operates as a financial holding company for Summit Community Bank, Inc. that provides community banking and other financial services to individuals and businesses primarily in the Eastern Panhandle, Southern and North Central regions of West Virginia and the Northern, and Shenandoah Valley and Southwestern regions of Virginia, and the Central region of Kentucky. The company's community banking services include demand, savings, and time deposits; commercial, commercial real estate, construction and land development, residential real estate, and consumer loans; and mortgage warehouse lines of credit, as well as trust and wealth management, cash management, and insurance brokerage services. As of December 31, 2020, it operated through 43 banking offices. The company was incorporated in 1987 and is headquartered in Moorefield, West Virginia.
Earnings Per Share
As for profitability, Summit Financial Group has a trailing twelve months EPS of $4.26.
PE Ratio
Summit Financial Group has a trailing twelve months price to earnings ratio of 5.53. Meaning, the purchaser of the share is investing $5.53 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.87%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is a negative 6.3% and a negative 12.9%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 15%, now sitting on 150.03M for the twelve trailing months.
4. Tesla (TSLA)
9.5% sales growth and 27.14% return on equity
Tesla, Inc. designs, develops, manufactures, leases, and sells electric vehicles, and energy generation and storage systems in the United States, China, and internationally. It operates in two segments, Automotive, and Energy Generation and Storage. The Automotive segment offers electric vehicles, as well as sells automotive regulatory credits; and non-warranty after-sales vehicle, used vehicles, retail merchandise, and vehicle insurance services. This segment also provides sedans and sport utility vehicles through direct and used vehicle sales, a network of Tesla Superchargers, and in-app upgrades; purchase financing and leasing services; services for electric vehicles through its company-owned service locations and Tesla mobile service technicians; and vehicle limited warranties and extended service plans. The Energy Generation and Storage segment engages in the design, manufacture, installation, sale, and leasing of solar energy generation and energy storage products, and related services to residential, commercial, and industrial customers and utilities through its website, stores, and galleries, as well as through a network of channel partners; and provision of service and repairs to its energy product customers, including under warranty, as well as various financing options to its solar customers. The company was formerly known as Tesla Motors, Inc. and changed its name to Tesla, Inc. in February 2017. Tesla, Inc. was incorporated in 2003 and is headquartered in Austin, Texas.
Earnings Per Share
As for profitability, Tesla has a trailing twelve months EPS of $3.08.
PE Ratio
Tesla has a trailing twelve months price to earnings ratio of 78.6. Meaning, the purchaser of the share is investing $78.6 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.14%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Tesla’s EBITDA is 8.01.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is a negative 22.9% and a negative 24.4%, respectively.
Previous days news about Tesla(TSLA)
- : fisker owners May charge EVs on Tesla chargers, company says. According to MarketWatch on Tuesday, 15 August, "Fisker Inc. FSR stock was up 1% in premarket trades on Tuesday after the electric vehicle maker said it will provide customers with access to Tesla Inc.’s TSLA supercharger network. ", "Fisker signed a service agreement with Tesla to adopt the North American Charging Standard (NACs) on its first vehicles in 2025. "
- According to Business Insider on Monday, 14 August, "However, this premium appears to be more reasonable when excluding heavyweights Amazon Inc. (NASDAQ:AMZN) and Tesla Inc. (TSLA)."
- Tesla (tsla) undercuts prices of two model Y EVs in China. According to Zacks on Tuesday, 15 August, "But Tesla started offering a cash rebate to new customers the very next day, following which China Association of Automobile Manufacturers, the association that brokered the agreement, withdrew the pledge."
- According to Zacks on Monday, 14 August, "CDNS also stated that it has collaborated with Tesla for development of the latter’s Dojo AI supercomputer."
